Deerfield Management Company, L.P. (Series C) Nuvalent, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 17,991,024 shares of NUVL stock, worth $1.38 Billion. This represents 31.57% of its overall portfolio holdings.
Number of Shares
17,991,024
Previous 17,991,024
-0.0%
Holding current value
$1.38 Billion
Previous $1.28 Billion
7.59%
% of portfolio
31.57%
Previous 32.3%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
225Shares Held
59.8MCall Options Held
191KPut Options Held
306K-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$404 Million18.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$347 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$232 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$138 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X01.78MShares$137 Million0.07% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.29B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...